Bulletin
Investor Alert

New York Markets After Hours

Elanco Animal Health Inc.

NYS: ELAN

GO
/marketstate/country/us

After Hours

 --Real time quotes

Oct 28, 2021, 4:52 p.m.

/zigman2/quotes/203710302/composite

$

32.90

Change

0.00 0.00%

Volume

Volume 140,676

Real time quotes

/zigman2/quotes/203710302/composite

Today's close

$ 33.31

$ 32.90

Change

-0.41 -1.23%

Day low

Day high

$31.16

$33.06

Open

52 week low

52 week high

$26.72

$37.49

Open

Company Description

Elanco Animal Health, Inc. engages in the innovation, development, manufacture and market products for companion and food animals. It offers products through the following four categories: Companion Animal Disease Prevention, Companion Animal Therapeutics, Food Animal Future Protein & Health, and Fo...

Elanco Animal Health, Inc. engages in the innovation, development, manufacture and market products for companion and food animals. It offers products through the following four categories: Companion Animal Disease Prevention, Companion Animal Therapeutics, Food Animal Future Protein & Health, and Food Animal Ruminants & Swine. The Companion Animal Disease Prevention category engages in the broadest parasiticide portfolios in the companion animal sector based on indications, species and formulations, with products that protect pets from worms, fleas and ticks. The Companion Animal Therapeutics category provides the details of broad pain and osteoarthritis portfolio across species, modes of action, indications and disease stages. The Food Animal Future Protein & Health category includes vaccines, nutritional enzymes and animal-only antibiotics, serves the growing demand for protein and includes innovative products in poultry and aquaculture production, where demand for animal health products is outpacing overall industry growth. It also focuses on developing functional nutritional health products that promote food animal health, including enzymes, probiotics and prebiotics. The Food Animal Ruminants & Swine category develops animal food products used in ruminant and swine production. The company was founded on May 3, 2018 and is headquartered in Greenfield, IN.

Valuation

Price to Sales Ratio

4.14

Price to Book Ratio

1.71

Enterprise Value to EBITDA

49.00

Enterprise Value to Sales

4.74

Total Debt to Enterprise Value

0.33

Efficiency

Revenue/Employee

348,223.00

Income Per Employee

-59,585.00

Receivables Turnover

3.33

Total Asset Turnover

0.25

Liquidity

Current Ratio

1.65

Quick Ratio

0.89

Cash Ratio

0.24

Profitability

Gross Margin

38.09

Operating Margin

-2.35

Pretax Margin

-20.53

Net Margin

-17.11

Return on Assets

-4.20

Return on Equity

-7.99

Return on Total Capital

-0.67

Return on Invested Capital

-5.06

Capital Structure

Total Debt to Total Equity

74.51

Total Debt to Total Capital

42.70

Total Debt to Total Assets

35.69

Long-Term Debt to Equity

67.53

Long-Term Debt to Total Capital

38.70

Officers and Executives

Name Age Officer Since Title
Mr. Jeffrey N. Simmons 51 2018 President, Chief Executive Officer & Director
Mr. Todd S. Young 47 2018 Chief Financial Officer & Executive Vice President
Mr. Shabbir Simjee - - Chief Medical Officer
Mr. Christopher Keeley - - Chief Information Officer & Senior Vice President
Mr. David S. Kinard 52 2018 Executive VP-Human Resources & Corporate Affairs

Insider Actions

– Purchase – Sale 1 – Number of Transactions
Date Name Shares Transaction Value
10/20/2021 Jeffrey N. Simmons
President, CEO and Director; Director
15,814   Derivative/Non-derivative trans. at $33.66 per share. 532,299
10/20/2021 David S. Kinard
See Remarks
2,065   Derivative/Non-derivative trans. at $33.66 per share. 69,507
10/20/2021 Aaron L. Schacht
Executive Vice President
2,065   Derivative/Non-derivative trans. at $33.66 per share. 69,507
10/20/2021 David Urbanek
See Remarks
3,042   Derivative/Non-derivative trans. at $33.66 per share. 102,393
10/20/2021 Ramiro M. Cabral
See Remarks
1,995   Derivative/Non-derivative trans. at $33.66 per share. 67,151
08/16/2021 R. David Hoover
See Remarks; Director
8,000   Acquisition at $31.45 per share. 251,600
08/13/2021 R. David Hoover
See Remarks; Director
2,000   Acquisition at $30.74 per share. 61,480
08/11/2021 Jeffrey N. Simmons
President, CEO and Director; Director
16,850   Acquisition at $29.7 per share. 500,445
08/11/2021 Michael J. Harrington
Director
3,000   Acquisition at $28.98 per share. 86,940
07/01/2021 Racquel Harris Mason
See Remarks
1,933   Derivative/Non-derivative trans. at $35 per share. 67,655
07/01/2021 De Simas Jose Manuel Correia
See Remarks
1,425   Derivative/Non-derivative trans. at $35 per share. 49,875
07/01/2021 Marcela A. Kirberger
See Remarks
8,572   Award at $0 per share. 0
06/03/2021 James M. Meer
Chief Accounting Officer
70   Derivative/Non-derivative trans. at $35 per share. 2,450
05/11/2021 R. David Hoover
See Remarks; Director
25,000   Acquisition at $32.44 per share. 811,000
05/11/2021 Art A. Garcia
Director
1,525   Acquisition at $32.88 per share. 50,142
03/05/2021 Jeffrey N. Simmons
President, CEO and Director; Director
74,374   Award at $0 per share. 0
03/02/2021 Jeffrey N. Simmons
President, CEO and Director; Director
8,879   Derivative/Non-derivative trans. at $32.34 per share. 287,146
03/02/2021 David S. Kinard
See Remarks
573   Derivative/Non-derivative trans. at $32.34 per share. 18,530
03/02/2021 Aaron L. Schacht
Executive Vice President
1,166   Derivative/Non-derivative trans. at $32.34 per share. 37,708
03/02/2021 Todd S. Young
See Remarks
1,723   Derivative/Non-derivative trans. at $32.34 per share. 55,721
03/02/2021 David Urbanek
See Remarks
630   Derivative/Non-derivative trans. at $32.34 per share. 20,374
03/02/2021 Michael-Bryant Hicks
See Remarks
880   Derivative/Non-derivative trans. at $32.34 per share. 28,459
03/02/2021 Ramiro M. Cabral
See Remarks
820   Derivative/Non-derivative trans. at $32.34 per share. 26,518
03/02/2021 James M. Meer
Chief Accounting Officer
337   Derivative/Non-derivative trans. at $32.34 per share. 10,898
03/01/2021 Jeffrey N. Simmons
President, CEO and Director; Director
4,883   Derivative/Non-derivative trans. at $33.65 per share. 164,312
03/01/2021 David S. Kinard
See Remarks
483   Derivative/Non-derivative trans. at $33.65 per share. 16,252
03/01/2021 Aaron L. Schacht
Executive Vice President
502   Derivative/Non-derivative trans. at $33.65 per share. 16,892
03/01/2021 Todd S. Young
See Remarks
949   Derivative/Non-derivative trans. at $33.65 per share. 31,933
03/01/2021 David Urbanek
See Remarks
425   Derivative/Non-derivative trans. at $33.65 per share. 14,301
03/01/2021 Michael-Bryant Hicks
See Remarks
799   Derivative/Non-derivative trans. at $33.65 per share. 26,886
03/01/2021 Ramiro M. Cabral
See Remarks
334   Derivative/Non-derivative trans. at $33.65 per share. 11,239
03/01/2021 James M. Meer
Chief Accounting Officer
84   Derivative/Non-derivative trans. at $33.65 per share. 2,826
03/01/2021 David S. Kinard
See Remarks
6,717   Award at $0 per share. 0
03/01/2021 Aaron L. Schacht
Executive Vice President
13,812   Award at $0 per share. 0
03/01/2021 Todd S. Young
See Remarks
15,669   Award at $0 per share. 0
03/01/2021 David Urbanek
See Remarks
7,876   Award at $0 per share. 0
03/01/2021 Ramiro M. Cabral
See Remarks
9,503   Award at $0 per share. 0
03/01/2021 Joyce J. Lee
Ex VP Prs US Pet Hlth Com Op
8,492   Award at $0 per share. 0
03/01/2021 Racquel Harris Mason
See Remarks
4,466   Award at $0 per share. 0
03/01/2021 De Simas Jose Manuel Correia
See Remarks
3,552   Award at $0 per share. 0
03/01/2021 Dirk Ehle
Ex VP & Pres Elanco Europe
2,792   Award at $0 per share. 0
03/01/2021 James M. Meer
Chief Accounting Officer
2,972   Award at $0 per share. 0
/news/latest/company/us/elan

MarketWatch News on ELAN

  1. Elanco Animal Health downgraded to hold from buy at Stifel Nicolaus

    8:14 a.m. Today

    - Tomi Kilgore

  2. Starboard Slashes Box Stake After Losing Proxy Battle

    9:31 p.m. Oct. 15, 2021

    - Barron's Online

  3. Elanco Health raises 2021 revenue outlook to $4.68 bln-$4.73 bln from $4.67 bln-$4.71 bln

    6:35 a.m. Aug. 9, 2021

    - Tomi Kilgore

  4. Elanco Health cuts 2021 adj. EPS outlook to 97 cents-$1.03 from $1.00-$1.06

    6:34 a.m. Aug. 9, 2021

    - Tomi Kilgore

  5. Elanco Health Q2 adj. EPS 28 cents; FactSet consensus 27 cents

    6:33 a.m. Aug. 9, 2021

    - Tomi Kilgore

  6. Elanco Health Q2 revenue $1.28 bln vs. $586 mln a year ago; FactSet consensus $1.24 bln

    6:33 a.m. Aug. 9, 2021

    - Tomi Kilgore

  7. Elanco Animal Health Q2 per-share loss 43 cents vs. loss 13 cents a year ago

    6:32 a.m. Aug. 9, 2021

    - Tomi Kilgore

  8. Kindred Biosciences shares soar 43% premarket

    6:42 a.m. June 16, 2021

    - Ciara Linnane

  9. Elanco expects deal to close in Q3

    6:40 a.m. June 16, 2021

    - Ciara Linnane

  10. Elanco still sees Q2 revenue $1.225 bln to $1.255 bln; full-year revenue $4.670 bln to $4.710 bln

    6:41 a.m. June 16, 2021

    - Ciara Linnane

  11. Elanco expects deal to be 'slightly dilutive' to adj. EPS in 2021 and 2022

    6:40 a.m. June 16, 2021

    - Ciara Linnane

  12. Elanco Animal Health to acquire Kindred Biosciences for about $440 mln

    6:39 a.m. June 16, 2021

    - Ciara Linnane

  13. Elanco Animal Health started at buy with $37 stock price target at Stifel Nicolaus

    6:56 a.m. April 15, 2021

    - Tomi Kilgore

  14. Elancos sales boosted by Bayer Animal health deal

    7:59 a.m. Feb. 24, 2021

    - MarketWatch.com

  15. Bayer to raise $1.65B through Elanco share sale

    3:18 a.m. Dec. 1, 2020

    - MarketWatch.com

  16. Elanco Animal Health stock price target raised to $41 from $31 at Morgan Stanley

    11:51 a.m. Nov. 23, 2020

    - Tomi Kilgore

  17. Loading more headlines...
/news/nonmarketwatch/company/us/elan

Other News on ELAN

  1. Elanco downgraded at Stifel citing near-term pressure on revenue

    12:11 p.m. Today

    - Seeking Alpha

  2. AVAH vs. ELAN: Which Stock Is the Better Value Option?

    11:40 a.m. Oct. 20, 2021

    - Zacks.com

  3. Got $5,000? Buy These 2 Cheap Growth Stocks Today

    10:30 a.m. Oct. 15, 2021

    - Motley Fool

  4. Zoetis Got Even More Expensive

    12:51 p.m. Oct. 14, 2021

    - Seeking Alpha

  5. This Pet Health Stock Is Down After Earnings -- Here's Why

    10:37 a.m. Sept. 7, 2021

    - Motley Fool

  6. Tracking George Soros' Portfolio - Q2 2021 Update

    6:11 a.m. Aug. 23, 2021

    - Seeking Alpha

  7. Wall Street Breakfast: The Week Ahead (Podcast)

    7:15 a.m. Aug. 22, 2021

    - Seeking Alpha

  8. Wall Street Breakfast: The Week Ahead

    7:04 a.m. Aug. 22, 2021

    - Seeking Alpha

  9. Elanco's Tangible Equity Units: Low-Risk Option With A 5% Yield

    8:00 a.m. Aug. 21, 2021

    - Seeking Alpha

  10. Loading more headlines...

At a Glance

Elanco Animal Health, Inc.

2500 Innovation Way

Greenfield, Indiana 46140

Phone

1 8773526261

Industry

Food Products

Sector

Consumer Goods

Fiscal Year-end

12/2021

Revenue

$3.27B

Net Income

$-560.10M

2020 Sales Growth

6.6%

Employees

9,400

/news/pressrelease/company/us/elan

Press Releases on ELAN

  1. Elanco Animal Health Inc ELAN Technical Data

    2:40 a.m. Oct. 20, 2021

    - Stock Traders Daily

  2. Elanco Animal Health Inc ELAN Technical Data

    6:38 a.m. Oct. 9, 2021

    - Stock Traders Daily

  3. Elanco Animal Health Inc ELAN Technical Data

    6:41 a.m. Sept. 29, 2021

    - Stock Traders Daily

  4. Elanco Animal Health Inc ELAN Trading Report

    12:13 p.m. Sept. 19, 2021

    - Stock Traders Daily

  5. Elanco Animal Health Inc (ELAN) Trading Report

    5:45 p.m. Sept. 9, 2021

    - Stock Traders Daily

  6. When Elanco Animal Health Inc (ELAN) Moves Investors should Listen

    9:08 p.m. Aug. 30, 2021

    - Stock Traders Daily

  7. Elanco Closes Acquisition of Kindred Biosciences

    6:45 a.m. Aug. 30, 2021

    - BusinessWire - BZX

  8. Learn to Evaluate Elanco Animal Health Inc (ELAN) using the Charts

    12:34 a.m. Aug. 20, 2021

    - Stock Traders Daily

  9. Loading more headlines...
Link to MarketWatch's Slice.